U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday.Shares of Quantum Computing Inc. (NASDAQ:QUBT) fell sharply in pre-market trading.Quantum Computing raised $750 million from institutional investors in market-priced private placement led by top shareholders.Quantum Computing shares dipped 11.7% to $21.70 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Rich Sparkle Holdings Ltd (NASDAQ:ANPA) tumbled 15% to $22.10 in pre-m ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday.Shares of Quantum Computing Inc. (NASDAQ:QUBT) fell sharply in pre-market trading.Quantum Computing raised $750 million from institutional investors in market-priced private placement led by top shareholders.Quantum Computing shares dipped 11.7% to $21.70 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Rich Sparkle Holdings Ltd (NASDAQ:ANPA) tumbled 15% to $22.10 in pre-m ...

PresentationGood morning, and welcome to the Larimar Therapeutics Conference Call. [Operator Instructions] Please be advised this call is being recorded at the company's request, and a replay will be available on the company's website. I would now like to turn the call over to Alexandra Folias of LifeSci Advisors. Please go ahead.Alexandra Folias Thank you, operator, and thank you all for participating in today's conference call. Before we start, I'd like to point out that there is a slide deck that accompa ...

PresentationGood morning, and welcome to the Larimar Therapeutics Conference Call. [Operator Instructions] Please be advised this call is being recorded at the company's request, and a replay will be available on the company's website. I would now like to turn the call over to Alexandra Folias of LifeSci Advisors. Please go ahead.Alexandra Folias Thank you, operator, and thank you all for participating in today's conference call. Before we start, I'd like to point out that there is a slide deck that accompa ...

Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injections of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich’s ataxia (FA).The OL study is evaluating the safety and tolerability, pharmacokinetics (PK), and FXN levels in skin and buccal cells, along with exploratory pharmacodynamic (PD) markers (lipid profiles) and cli ...

Larimar Therapeutics (NasdaqGM:LRMR) Update / Briefing September 29, 2025 08:00 AM ET Company ParticipantsAlexandra Folias - Managing Director - United StatesCarole Ben-Maimon - President, CEO & DirectorJoori Park - VP - Equity ResearchJon Wolleben - Managing DirectorConference Call ParticipantsYatin Suneja - Senior MD & Biotechnology AnalystSamantha Semenkow - VP - SMid Biotech Equity Research AnalystJoon Lee - MD & Senior Biotech AnalystMyles Minter - Research Analyst - HealthcareCory Jubinville - MD & Re ...

Larimar Therapeutics, Inc. (LRMR), Monday announced encouraging data from the ongoing long-term open label or OL study, evaluating daily subcutaneous injections of nomlabofusp in participants with Friedreich's ataxia, a rare, progressive, and systemic disease with neurologic deterioration. During the study, participants were initially administered 25 mg of nomlabofusp daily. Later, the dose was increased to 50 mg in the fourth quarter of 2024. The data showed that nomlabofusp increases skin frataxin or FXN ...

Larimar Therapeutics Program Update September 2025 1 pro Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( "Company") and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited to Larimar's ability to develop and commercialize nomlabofusp (CTI-1601) and any other ...

In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)Consistent directional improvement across 4 key clinica ...

Core Insights - Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound nomlabofusp targeting Friedreich's ataxia [3]. Group 1: Company Overview - Larimar Therapeutics is listed on Nasdaq under the ticker LRMR and is dedicated to addressing complex rare diseases [3]. - The company is developing nomlabofusp as a potential treatment for Friedreich's ataxia and plans to utilize its intracellular delivery platform for designing other fusion proteins targeting additional rare diseases [3]. Group 2: Upcoming Events - Larimar will host a conference call and webcast on September 29, 2025, at 8:00 am EDT to discuss updates on the nomlabofusp clinical development program, including data from an ongoing long-term open label study [1][2].